{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Plasma concentrations of GSK525762 in relationship with safety and efficacy parameters derived from PK/PD model was planned to be analyzed.","groups":[{"description":"Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG000","title":"Part 2: GSK525762 60 mg QD CTCL"},{"description":"Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762","id":"OG001","title":"Part 2: GSK525762 75 mg QD MDS"},{"description":"Participants CTCL were administered once daily oral dose of 80 mg GSK525762","id":"OG002","title":"Part 2: GSK525762 80 mg QD CTCL"}],"populationDescription":"PK Population. This was an other pre-specified outcome measure. Data was not analyzed and reported.","reportingStatus":"POSTED","timeFrame":"Up to 36.4 weeks","title":"Part 2: Plasma Concentrations of GSK525762 in Relationship With Safety and Efficacy Parameters Derived From Pharmacokinetic/Pharmacodynamic (PK/PD) Model","type":"OTHER_PRE_SPECIFIED"}